Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$125.65 USD
+0.65 (0.52%)
Updated Nov 22, 2024 03:59 PM ET
After-Market: $127.58 +1.93 (1.54%) 7:58 PM ET
3-Hold of 5 3
C Value A Growth F Momentum B VGM
Price, Consensus and EPS Surprise
NBIX 125.65 +0.65(0.52%)
Will NBIX be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for NBIX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for NBIX
Xenon Q3 Loss Narrower Than Expected, Pipeline Development in Focus
Neurocrine (NBIX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
NBIX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Neurocrine Biosciences (NBIX) Q3 Earnings Miss Estimates
Implied Volatility Surging for Neurocrine Biosciences (NBIX) Stock Options
Neurocrine Biosciences (NBIX) Earnings Expected to Grow: Should You Buy?
Other News for NBIX
Franklin Biotechnology Discovery Fund Q3 2024 Commentary
Neurocrine (NBIX) Gets a Buy from Stifel Nicolaus
BB Biotech AG's Strategic Acquisition in Molecular Templates Inc
Voyager Therapeutics' Tracer Platform Targets CNS Market: Here's Why I'm Neutral
Voyager Therapeutics' TRACER Platform Targets CNS Market: Here's Why I'm Neutral